BridgeBio Pharma, Inc.
NASDAQ:BBIOBiotechnology
+$0.75 today
- Market cap
- $15.20B
- Beta
- 0.97
- P/E (TTM)
- -18.1
- EPS (TTM)
- -$3.73
Volume 3.55M
Average 2.49M
BBIO Interest Income
Income earned on cash, deposits, and investments held by the company.
BridgeBio Pharma, Inc.NASDAQ: BBIO
Interest Income · Q2 FY2026 · quarter ended Jun 2026
Interest income growth accelerates
Q2 FY2026 interest income of $6.66M rose 70.8% year over year, ahead of the +36.0% change in trailing-twelve-month interest income. Sequentially, it rose 6.6% from the prior quarter. Over 3 fiscal years it compounded at +38.1% a year.
Context
- Interest income amounted to 4.0% of revenue in FY2025, down 3.8 pp from a year earlier.
- Interest income increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +70.8% holds above the trailing-twelve-month pace of +36.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 19.85M USD
- Year-over-year change
- +15.1%
- 4-year CAGR
- +104.6%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.85M | +15.1% |
| FY2024 | 2024-12-31 | 17.25M | -4.4% |
| FY2023 | 2023-12-31 | 18.04M | +139.2% |
| FY2022 | 2022-12-31 | 7.54M | +565.7% |
| FY2021 | 2021-12-31 | 1.13M | — |
Interest Income vs competitors
How BBIO compares with its peers on the latest reported figures
- Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +36.0% is the 5th highest of 10, against a peer median of -7.8%.
- Interest income amounts to 3.3% of revenue for BBIO, versus a peer median of 4.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $4.68B USD | +6281.3% | +60.7% | 0.5% | |
| LTM Jun 2026 | $110.05M USD | -7.8% | +65.0% | 2.3% | |
| LTM Sep 2026 | $89.99M USD | -11.7% | +56.9% | 9.4% | |
| LTM Sep 2026 | €56.37M EUR | +172.4% | +25.6% | 4.7% | |
| LTM Jun 2026 | $28.36M USD | -48.1% | +42.7% | 786.9% | |
| LTM Mar 2026 | $24.17M USD | -30.0% | +31.2% | 3.6% | |
| LTM Jun 2026 | $23.48M USD | +36.0% | +38.1% | 3.3% | |
| LTM Sep 2026 | $14.65M USD | +138.4% | — | 2570.2% | |
| LTM Mar 2026 | $12.38M USD | +77.1% | +79.8% | 61.9% | |
| LTM Sep 2026 | $12.24M USD | -12.1% | +26.6% | 1.9% | |
| LTM Jun 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding BBIO) | — | -7.8% | +49.8% | 4.1% | |
Competitors are the stored peer set for BBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 69.72M | 77.65M | 9.3M | 221.9M | 502.08M |
| Cost of Revenue | 3.11M | 3.43M | 2.45M | 3.88M | 28.27M |
| Gross Profit | 66.6M | 74.21M | 6.86M | 218.02M | 473.81M |
| Gross Margin | 95.5% | 95.6% | 73.7% | 98.3% | 94.4% |
| Research & Development | 451.02M | 399.46M | 455.71M | 506.46M | 477.54M |
| Selling, General & Admin | 192.21M | 143.19M | 150.59M | 288.93M | 555.14M |
| Operating Expenses | 643.23M | 586.42M | 614.23M | 811M | 1.04B |
| Depreciation & Amortization | 5.84M | 6.77M | 6.49M | 6.08M | 5.43M |
| EBITDA | (533.83M) | (397.44M) | (565.47M) | (436.83M) | (676.45M) |
| EBITDA Margin | -765.7% | -511.9% | -6078.3% | -196.9% | -134.7% |
| Operating Income | (576.63M) | (512.2M) | (607.37M) | (592.97M) | (569.09M) |
| Operating Margin | -827.1% | -659.6% | -6528.8% | -267.2% | -113.3% |
| Interest Income | 1.13M | 7.54M | 18.04M | 17.25M | 19.85M |
| Interest Expense | 46.78M | 80.44M | 81.29M | 99.29M | 53.1M |
| Other Income / Expenses | (9.82M) | 27.55M | (45.88M) | 50.78M | (165.9M) |
| Income Before Tax | (586.45M) | (484.65M) | (653.25M) | (542.19M) | (734.99M) |
| Pre-Tax Margin | -841.2% | -624.2% | -7021.9% | -244.3% | -146.4% |
| Income Tax Expense | 0 | 0 | 0 | 1.15M | 555K |
| Net Income | (562.54M) | (481.18M) | (643.2M) | (535.76M) | (729.31M) |
| Net Margin | -806.9% | -619.7% | -6913.9% | -241.4% | -145.3% |
| EPS (Basic) | (3.90) | (3.35) | (3.95) | (2.88) | (3.79) |
| EPS (Diluted) | (3.90) | (3.35) | (3.95) | (2.88) | (3.79) |
| Weighted Avg Shares | 144.36M | 147.47M | 162.79M | 186.08M | 197.24M |
| Weighted Avg Shares (Diluted) | 144.36M | 147.47M | 162.79M | 186.08M | 197.24M |
BridgeBio Pharma, Inc.
NASDAQ:BBIO
Intrinsic Alpha fair value
Locked
Current Price
$78.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.